CHILDREN'S DIMETAPP COLD & ALLERGY CHEWABLE TABLETS OTC
Generic Name and Formulations:
Brompheniramine maleate 1mg, phenylephrine HCl 2.5mg; per tab; alcohol-free; grape flavor.
Pfizer Consumer Healthcare
Indications for CHILDREN'S DIMETAPP COLD & ALLERGY CHEWABLE TABLETS:
Rhinorrhea, allergy symptoms, nasal congestion.
<6yrs: do not use. 6–11yrs: chew 2 tabs every 4 hours; max 6 doses/24 hours.
Children <6yrs old. During or within 14 days of MAOIs. For use as a sedative hypnotic.
Hypertension. Cardiovascular disease. Thyroid disease. Diabetes. Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
Antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants. Avoid alcohol.
Drowsiness, anticholinergic effects, dizziness, nervousness, insomnia, excitability in children.
Syrup—4oz, 8oz (w. dosing cup)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC